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Abstract
Aims: Epigenetic mechanisms, including histone post-translational modifications and DNA methylation, are
implicated in the pathogenesis of diabetic nephropathy (DN), but the mediators are not well known. Moreover,
although dyslipidemia contributes to DN, epigenetic changes triggered by lipids are unclear. In diabetes, increased
expression of 12/15-lipoxygenase (12/15-LO) enhances oxidized lipids such as 12(S)-hydroxyeicosatetraenoic
acid [12(S)-HETE], which promote oxidant stress, glomerular and mesangial cell (MC) dysfunction, and fibrosis,
and mediate the actions of profibrotic growth factors. We hypothesized that 12/15-LO and its oxidized lipid
products can regulate epigenetic mechanisms mediating profibrotic gene expression related to DN. Results: 12(S)-
HETE increased profibrotic gene expression and enrichment of permissive histone lysine modifications at their
promoters in MCs. 12(S)-HETE also increased protein levels of SET7, a histone H3 lysine 4 methyltransferase,
and promoted its nuclear translocation and enrichment at profibrotic gene promoters. Furthermore, SET7 (Setd7)
gene silencing inhibited 12(S)-HETE-induced profibrotic gene expression. 12/15-LO (Alox15) gene silencing or
genetic knockout inhibited transforming growth factor-b1 (TGF-b1)-induced expression of Setd7 and profibrotic
genes and histone modifications in MCs. Furthermore, 12/15-LO knockout in mice ameliorated key features of
DN and abrogated increases in renal SET7 and profibrotic genes. Additionally, 12/15-LO siRNAs in vivo blocked
increases in renal SET7 and profibrotic genes in diabetic mice. Innovation and Conclusion: These novel results
demonstrate for the first time that 12/15-LO-derived oxidized lipids regulate histone modifications associated with
profibrotic gene expression in MCs, and 12/15-LO can mediate similar actions of TGF-b1 and diabetes. Targeting
12/15-LO might be a useful strategy to inhibit key epigenetic mechanisms involved in DN. Antioxid. Redox
Signal. 24, 361–375.
Introduction
D iabetic nephropathy (DN) is a major renal compli-cation that can lead to end-stage kidney disease and in-
creased mortality (13). Mesangial cell (MC) hypertrophy,
fibrosis, and oxidant stress mediated by high glucose (HG)
and downstream growth factors such as transforming growth
factor-b (TGF-b) are key events in the progression of DN (16,
28, 46, 50, 63). TGF-b regulates the expression of several
profibrotic and cell cycle genes through activation of key
transcription factors such as Smad and E-box-binding pro-
teins in MCs and other renal cells (18, 25, 29, 49). Emerging
evidence shows that epigenetic mechanisms, such as chro-
matin histone post-translational modifications (PTMs) (24)
and DNA methylation (14), play important roles in the reg-
ulation of profibrotic and inflammatory genes related to the
pathogenesis of DN (44, 53). These studies demonstrated that
TGF-b promotes changes in histone lysine modifications at
profibrotic gene promoters and also mediates similar epige-
netic changes induced by HG. These include enrichment of
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permissive histone modifications associated with transcrip-
tion activation (histone H3 lysine-4 methylation [H3K4me]
and histone H3 lysine-9 acetylation [H3K9Ac]), inhibition of
repressive histone modifications (H3K9me), and increased
expression, as well as enrichment of SET7 (Setd7), a key
histone H3K4 methyltransferase, at profibrotic gene promoters
in MCs (52, 62). Changes in certain histone modifications and
corresponding writer enzymes (methyltransferases and acet-
ylases) were also shown in kidneys and glomeruli from ex-
perimental models of DN (23, 43, 62). Treatment with histone
deacetylase (HDAC) inhibitors blocked progression of DN in
mice (1, 35). Furthermore, treatment of diabetic mice with
the angiotensin II (Ang II) type I receptor (AT1R) blocker,
losartan, ameliorated proteinuria and pathological gene expres-
sion in kidneys, but reversed only some of the diabetes-induced
changes in various histone modifications (43). Together, these
studies support a key role for epigenetic mechanisms in DN and
suggest that inhibition of these mechanisms might improve the
efficacy of currently available therapies. However, the precise
mechanisms and mediators involved in epigenetic regulation of
profibrotic genes by TGF-b and diabetes are still unclear.
Diabetes and obesity are associated with increased levels of
oxidized lipids derived from the metabolism of polyunsatu-
rated fatty acids (2, 8, 15, 32, 51). These oxidized lipids can
promote oxidant stress, inflammation, fibrosis, and hypertro-
phy associated with vascular complications (8, 15, 32, 40, 45,
47, 57). However, it is not known if they can also regulate
profibrotic genes via epigenetic mechanisms. Previous studies
showed that increased expression and activation of 12/15-
lipoxygenase (12/15-LO), the mouse homolog of human 15-
LO, play an important role in increasing oxidized lipids in
diabetes (8, 15, 32, 40, 47). 12/15-LO is a nonheme iron-
containing enzyme that metabolizes arachidonic acid to gen-
erate oxidized lipids such as 12(S)-hydroxyeicosatetraenoic
acid [12(S)-HETE] and 15-HETE (10, 33, 60). 12/15-LO has
been implicated in several diabetic complications, including
DN (8, 15, 32, 36, 40, 54, 57, 61). 12(S)-HETE levels are
increased by HG and TGF-b in MCs in vitro and in experi-
mental DN (15, 40, 57). 12/15-LO-derived 12(S)-HETE can
promote hypertrophy and expression of profibrotic and
proinflammatory genes, TGF-b, and AT1R in MCs (15, 40,
57–59). 12(S)-HETE regulates gene expression via CREB and
Smad transcription factors and can augment similar actions of
TGF-b in MCs (22, 40). 12/15-LO deficiency attenuated TGF-
b signaling in MCs, further confirming a cross talk between 12/
15-LO and TGF-b (21). Furthermore, administration of a
cholesterol-tagged 12/15-LO siRNA ameliorated glomerular
dysfunction and expression of renal TGF-b and profibrotic
genes in diabetic mice (61). These results demonstrate the
pathological role of the 12/15-LO pathway in the progression
of DN via direct actions as well as cross talk with HG or
diabetes-induced TGF-b.
However, it is unknown whether 12/15-LO activation and
its oxidized lipid products such as 12(S)-HETE can enrich
permissive histone modifications at profibrotic genes in MCs
and whether 12/15-LO mediates similar epigenetic changes
induced by TGF-b and diabetes. In this study, we demon-
strated that 12(S)-HETE treatment directly induces enrich-
ment of histone lysine modifications associated with
transcriptional activation at profibrotic gene promoters and
that it also regulates the expression of SET7 and promotes its
nuclear translocation, as well as enrichment, at profibrotic
gene promoters in MCs. Furthermore, using loss-of-function
approaches with 12/15-LO knockout (LOKO) mice and
siRNAs, we showed that 12/15-LO can mediate TGF-b-
induced histone modifications in vitro in MCs and diabetes-
induced renal changes in vivo in mouse models of DN.
Results
12(S)-HETE-induced profibrotic gene expression
is associated with enhanced enrichment of promoter
H3K9Ac and H3K4me in rat mesangial cell
We first tested whether 12(S)-HETE-induced profibrotic
gene expression in MCs is associated with alteration in key
promoter histone modifications. We treated serum-depleted
(SD) rat mesangial cells (RMC) with 12(S)-HETE (10-7 M)
or vehicle (ethanol) and analyzed the expression of profi-
brotic genes using real-time quantitative polymerase chain
reactions (RT-qPCRs) and histone modifications at their pro-
moters using chromatin immunoprecipitation (ChIP) assays
with specific antibodies. Results showed that 12(S)-HETE
significantly upregulated Serpine1, Ctgf, and Col1a1 mRNAs
from 2 to 24 h compared with vehicle controls (Fig. 1A–C).
This effect was specific to 12(S)-HETE since its stereoiso-
mer, 12(R)-HETE, which is not an LO metabolite, had no
effect on the expression of these profibrotic genes (Fig. 1D).
We have also confirmed increased levels of Serpine1 (plas-
minogen activator inhibitor type 1) protein levels after
treatment with 12(S)-HETE by Western blotting (Supple-
mentary Fig. S1; Supplementary Data are available online at
www.liebertpub.com/ars). These results confirmed that 12/
15-LO products upregulate profibrotic gene expression in
MCs related to the pathogenesis of DN.
Furthermore, ChIP assays showed that 12(S)-HETE in-
duced significant enrichment of permissive histone modifi-
cations, including H3K9Ac (Fig. 2A–C), H3K4me1 (Fig.
2D–F), and H3K4me3 (Fig. 2G–I), at the profibrotic gene
promoters compared with controls (SD) in a time-dependent
manner. However, no significant changes were seen at the
cyclophilin A (CypA, Ppia) promoter, tested as a control for
specificity (Supplementary Fig. S2A–C). 12(S)-HETE also
had no effect on H3K4me2 (Supplementary Fig. S2D, E).
These results suggest that the promoter enrichment of chro-
matin marks known to be associated with active gene
Innovation
12/15-Lipoxygenase (12/15-LO) plays key roles in fi-
brosis and hypertrophy induced by transforming growth
factor beta1 (TGF-b1) in renal mesangial cells related to
diabetic nephropathy. In this study we report the in-
volvement of epigenetic mechanisms in these actions of
12/15-LO. We demonstrated that oxidized lipids derived
from 12/15-LO can enhance active histone modifications
and regulate H3K4-methyl transferase SET7 to promote
fibrotic gene expression. 12/15-LO could also mediate
similar actions of TGF-b1. Genetic knockout or siRNA
targeting 12/15-LO inhibited renal glomerular dysfunc-
tion, fibrosis and SET7 expression in diabetic mice. Thus,
targeting12/15-LO could be a novel approach to reverse
epigenetic mechanisms mediating diabetic renal dys-
function.
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expression, namely H3K9Ac, H3K4me1, and H3K4me3,
may be involved in upregulation of profibrotic genes by ox-
idized lipids such as 12(S)-HETE in MCs.
SET7 regulation by 12(S)-HETE in RMC
Because 12(S)-HETE enhanced H3K4me1 levels at pro-
fibrotic gene promoters, we next examined the role of the
related methyltransferase SET7. SET7 regulates H3K4me1
in mammalian cells and evidence shows that its expression,
nuclear translocation, and recruitment at key pathological
genes are increased under diabetic conditions (9, 27, 37, 52).
However, its regulation by oxidized lipids has not been
studied. Our results showed that 12(S)-HETE treatment in-
creased SET7 protein levels in MCs (Fig. 3A). Furthermore,
immunoblotting of nuclear extracts (Fig. 3B) and immuno-
fluorescence (IF) studies (Fig. 3C) showed that 12(S)-HETE
enhanced SET7 nuclear translocation in RMC. ChIP assays
showed that 12(S)-HETE also increased SET7 occupancy at
the Serpine1 and Ctgf promoters in RMC (Fig. 3D, E). To
further confirm the role of SET7, we transfected RMC with
siRNAs targeting SET7 (siSET7) or control siNTC oligonu-
cleotides and examined the effect of SET7 gene silencing on
12(S)-HETE-induced gene expression. Results showed that
SET7 gene silencing (Fig. 3F) significantly inhibited 12(S)-
HETE-induced profibrotic gene expression (Fig. 3G–I). Thus,
for the first time, these data demonstrate direct regulation
of SET7 expression and activation by oxidized lipids in
mammalian cells, indicating a role for 12/15-LO activa-
tion in triggering epigenetic mechanisms involved in DN
development.
12/15-LO gene silencing attenuates TGF-b-induced
SET7 and profibrotic gene expression in RMC
We have previously demonstrated that 12/15-LO and
TGF-b regulate each other and that such cross talk between
them augments gene expression involved in DN (22). Since
evidence also shows that TGF-b-induced SET7 can mediate
profibrotic gene expression (52), we next examined whether
12/15-LO regulates TGF-b-induced SET7 by using loss-of-
function approaches. RMCs were transfected with siRNAs
targeting 12-LO (si12-LO) or control siRNA (siNTC), and
TGF-b (10 ng/ml, for 6 h)-induced gene expression was an-
alyzed. Transfection with si12-LO significantly reduced 12/
15-LO (Alox15) gene expression (Fig. 4A) and also inhibited
both basal and TGF-b-induced Set7 (Setd7) mRNA expres-
sion (Fig. 4B) compared with siNTC-transfected RMCs.
Furthermore, TGF-b-induced expression of Serpine1 and
Ctgf was significantly attenuated in RMCs transfected with
si12-LO (Fig. 4C, D). These results demonstrate that 12/15-
LO can regulate TGF-b-induced SET7 and profibrotic gene
expression.
TGF-b-induced profibrotic gene expression
and enrichment of key histone modifications
at their promoters are attenuated in MCs derived
from LOKO mice
To further confirm the role of 12/15-LO in TGF-b-
induced epigenetic mechanisms, we tested cells from
12/15-LOKO mice (21). We treated MCs isolated from
wild-type mice (WT-MC) and LOKO mice (LOKO-MC)
A B
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FIG. 1. 12(S)-HETE induces pro-
fibrotic genes in RMCs. RMCs were
SD and treated with vehicle ethanol
or 12(S)-HETE (10-7 M) for the in-
dicated time points, and expression
of profibrotic genes, including Ser-
pine1 (A), Ctgf (B), and Col1a1 (C),
was determined by RT-qPCR. (D) SD
RMCs were stimulated with vehicle,
12(S)-HETE (10-7 M), or 12(R)-HETE
(10-7 M) for 2 h, and profibrotic gene
expression was analyzed by RT-qPCR.
Data represent mean – SEM of three
independent experiments. #p < 0.01
versus SD vehicle-treated control,
$p < 0.01 versus 12(R)-HETE. 12(S)-
HETE, 12(S)-hydroxyeicosatetraenoic
acid; RMC, rat mesangial cell; RT-
qPCR, real-time quantitative poly-
merase chain reaction; SD, serum
depleted; SEM, standard error of the
mean.
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with TGF-b (10 ng/ml) and analyzed the expression of
TGF-b target genes. Results showed that TGF-b treat-
ment significantly increased expression of profibrotic
genes, Serpine1 and Ctgf, as well as Setd7 in WT-MC,
but these increases were significantly attenuated in
LOKO-MC (Fig. 5A–C). In contrast, Ppia expression
was not affected in these treatments (Fig. 5D). Further-
more, ChIP assays revealed that TGF-b (10 ng/ml, for
2 h) increased H3K9Ac and H3K4me1 enrichment at the
Serpine1, Ctgf, and Col1a1 promoters in WT-MC, but
these events were significantly attenuated or completely
blocked in LOKO-MC (Fig. 5E–J). These results dem-
onstrate that the 12/15-LO pathway plays a mediatory
role in TGF-b-induced epigenetic histone modifications





FIG. 2. 12(S)-HETE induces permissive histone modifications (H3K9Ac and H3K4me) at profibrotic gene pro-
moters. Bar graphs showing relative enrichment of permissive histone modifications at indicated gene promoters induced
by 12(S)-HETE compared with SD controls at different time points. (A–C) H3K9Ac; (D–F) H3K4me1; (G–I) H3K4me3.
RMCs were treated with 12(S)-HETE (10-7 M) for different time points and ChIP assays were performed with H3K9Ac,
H3K4me1, and H3K4me3 antibodies. ChIP-enriched DNA was amplified by qPCR using primers spanning the promoter
regions of indicated profibrotic genes. Results were normalized to input and expressed as fold over SD controls. Data
represent mean – SEM, #p < 0.01 versus SD, n = 3. ChIP, chromatin immunoprecipitation; H3K9Ac, histone H3 lysine-9
acetylation; H3K4me1, histone H3 lysine-4 monomethylation; H3K4me3, histone H3 lysine-4 trimethylation.
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12/15-LO deficiency in vivo attenuates increased
expression of SET7 and profibrotic genes
and ameliorates key features of DN in mice
Next, we examined the in vivo relevance of these results
using WT and LOKO mice rendered diabetic by sequential
injections of streptozotocin (STZ) as described earlier (61).
In parallel, control mice were injected with citrate buffer.
Control (no streptozotocin [NS]) and diabetic (STZ) mice
were monitored up to 16 weeks. Diabetic WT as well as
diabetic LOKO mice exhibited hyperglycemia, polyuria, and
some weight loss, but no significant differences were ob-
served in these and other physiological or biochemical pa-
rameters between the two groups (Tables 1 and 2). Diabetic
WT and LOKO mice showed significant increases in pro-
teinuria at 12 and 16 weeks relative to nondiabetic controls.
However, the degree of proteinuria was relatively less in
diabetic LOKO mice compared with diabetic WT mice at
both time points (Table 2). Whereas the albumin-to-
creatinine ratio (ACR) was significantly increased in diabetic
WT mice at 12 and 16 weeks postdiabetes (Fig. 6A), in
contrast, ACR was significantly increased only at 12 weeks,
but not at 16 weeks, in diabetic LOKO mice (Fig. 6A).
Diabetic WT mice exhibited kidney hypertrophy, including
increased kidney-to-body weight ratio (Table 1) and me-
sangial expansion characterized by increased periodic acid-
Schiff-positive matrix accumulation, as well as increased
glomerular area, but these parameters were significantly
FIG. 3. Regulation of SET7 by 12(S)-HETE in MCs. (A) Quiescent RMCs were treated with 12(S)-HETE (10-7 M) and
at indicated time points, SET7 protein levels in whole cell lysates were determined by immunoblotting with SET7 antibody.
Actin was used as an internal control. Results are representative of two separate experiments. Intensity of SET7 bands was
quantified using Bio-Rad GS-900 densitometer and expressed as fold over control (SD) cells (shown below each lane).
Results are representative of two separate experiments. (B) Quiescent RMCs were treated with 12(S)-HETE (10-7 M), and at
indicated time points, SET7 levels in nuclear fractions were determined by immunoblotting with SET7 antibody. Lamin B
was used as an internal control. Intensity of nuclear SET7 bands was quantified using Bio-Rad GS-900 densitometer and
expressed as fold over control (SD) cells (shown below each lane). Results are representative of two separate experiments.
(C) RMCs were treated with 12(S)-HETE (10-7 M) or equal volume of vehicle (ethanol) for 6 h, and nuclear localization of
SET7 was determined by immunofluorescence staining with SET7 antibody, followed by rabbit anti-mouse antibody
conjugated with FITC (green) (upper panels). Blue color in lower panels indicates nuclear staining with DAPI. (D, E)
RMCs were treated with 12(S)-HETE (10-7 M) for indicated time points and ChIP assays were performed with SET7
antibody to evaluate its enrichment at Serpine1 (D) and Ctgf promoters (E). ChIP DNA was analyzed by qPCR and results
normalized to input are expressed as fold over SD controls. Data represent mean – SEM. #p < 0.01 versus SD. n = 3. (F)
SET7 gene silencing using siRNAs in RMCs. RMCs were transfected with siRNAs targeting SET7 (siSET7) or nontargeting
control (siNTC) oligonucleotides. Gene expression was analyzed 96 h after transfection. Data represent mean – SEM.
*p < 0.05 versus siNTC. n = 3. (G–I) Effect of SET7 gene silencing on 12(S)-HETE-induced fibrotic genes. RMCs were
transfected with siSET7 or siNTC and 96 h post-transfection, stimulated with vehicle (Ctrl) or 12(S)-HETE (10-7 M) for 8 h,
and expression of indicated genes was analyzed by RT-qPCR. Results are expressed as fold over siNTC-Ctrl. Data represent
mean – SEM. *p < 0.05 versus siNTC-Ctrl and $p < 0.05 versus siSET7-Ctrl. n = 3. To see this illustration in color, the reader
is referred to the web version of this article at www.liebertpub.com/ars
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ameliorated in diabetic LOKO mice compared with diabetic
WT mice (Fig. 6B, C).
Furthermore, immunohistochemical (IHC) analysis of kid-
ney sections revealed increased glomerular expansion (Fig.
6D, panel 2), extracellular matrix (ECM) accumulation and
basement membrane thickening (Fig. 6D, panel 6), interstitial
fibrosis and glomerulosclerosis (Fig. 6D, panel 10), and glo-
merular expression of TGF-b (Fig. 6D, panel 14) in diabetic
WT mice (WT+STZ) versus controls (WT+NS). However, all
these pathological features of DN were attenuated in the kid-
neys of diabetic LOKO mice (LOKO+STZ) compared with
diabetic WT mice (16 weeks postdiabetes) (Fig. 6D, panels 4,
8, 12, and 16). Figure 6E and F shows quantitative analyses of
trichrome staining (interstitial fibrosis) and TGF-b staining,
respectively. Thus, key pathological characteristics of DN
were clearly attenuated in diabetic LOKO mice, further sup-
porting the notion that 12/15-LO deficiency in vivo confers
renal protection during diabetes. These results are also con-
sistent with the mRNA results in MCs derived from the LOKO
mice (Figs. 4 and 5), demonstrating that the 12/15-LO gene
knockout attenuates diabetes-induced TGF-b expression as
well as associated mesangial matrix gene expression.
Diabetes increases renal expression of profibrotic
genes and SET7 in WT mice, but these effects are
attenuated in 12/15-LO-deficient mice
Next, we examined if diabetes-induced upregulation of
profibrotic genes is associated with parallel increases in SET7
expression. RT-qPCR results showed that expression of
several profibrotic genes was significantly increased in glo-
meruli from diabetic WT mice relative to nondiabetic WT
controls, but these increases were significantly attenuated or
abrogated in diabetic LOKO mice compared with diabetic
WT mice (Fig. 7A). Furthermore, Setd7 mRNA levels were
also significantly increased in kidneys of diabetic WT mice
(cortex and glomeruli), but this effect was abrogated in dia-
betic LOKO mice (Fig. 7B). These changes in gene expres-
sion were further confirmed by Western blotting using
protein samples from glomeruli (Fig. 7C) and renal cortex
(Fig. 7D) of these mice. Some increase in basal protein levels
observed in the LOKO mice, especially in the cortical sam-
ples, could be due to heterogeneity of these tissues. Overall,
these results demonstrate that the 12/15LO pathway plays an
important role in vivo in the regulation of SET7 and profi-
brotic genes in DN.
To further explore the functional role of 12/15-LO in the
regulation of SET7 in DN, we examined SET7 expression in
diabetic WT mice treated in vivo with cholesterol-tagged
si12-LO or control mismatched siRNA (siMM). Our previous
studies showed that treatment of diabetic mice with this
siRNA ameliorated features of DN and inhibited profibrotic
gene expression in vivo (61). Renal cortex samples from these
12-LO siRNA and control siRNA-treated mice (61) were
analyzed by RT-qPCR and Western blotting. Results showed
that Setd7 mRNA levels were increased in kidneys of diabetic
mice (STZ) compared with nondiabetic controls (NS) (Fig.
7E), but these diabetes-induced increases in Setd7 expression
were significantly ameliorated in diabetic mice treated with
si12-LO (si12-LO+STZ) compared with nontargeting mis-
matched control oligos (siMM+STZ) (Fig. 7E). Furthermore,
diabetes induced upregulation of SET7 and profibrotic Ser-
pine1 protein levels were also ameliorated by si12-LO
treatment (Fig. 7F). Because, si12-LO also ameliorated DN
in these mice (61), these results indicate that 12/15-LO could
be a potential therapeutic target to inhibit diabetes-induced
epigenetic changes involved in profibrotic gene expression
and DN progression.
Discussion
The rapid rise in diabetes and obesity has led to signifi-
cantly greater incidence and severity of DN. Since changes in
the environment and lifestyles are likely key contributors,
epigenetic mechanisms are increasingly implicated (12, 18).
However, although dyslipidemia is involved in DN, the
contribution of oxidized lipids to epigenetic mechanisms in
DN has not been evaluated. In this study, we report for the
A B
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FIG. 4. siRNAs targeting 12/15-LO attenuated TGF-b-
induced profibrotic genes and SET7 expression. (A)
RMCs were transfected with 0.3 lg of siRNA targeting 12/
15-LO (si12-LO) or control (siNTC) oligonucleotides, and
48 h later, 12/15-LO (Alox15) mRNA expression was de-
termined by RT-qPCR. 12/15-LO mRNA levels were ex-
pressed as fold over siNTC (mean – SEM; #p < 0.01 vs.
siNTC, unpaired t-test, n = 3). (B–D) RMCs were trans-
fected with 0.3 lg of si12-LO or siNTC oligonucleotides,
48 h post-transfection, SD for 24 h, and then treated with
TGF-b (10 ng/ml) for 6 h. Expression of Setd7 (B) and
profibrotic genes (C, D) was determined by RT-qPCR. b-
Actin was used as internal control. The results are expressed
as fold over siNTC control (mean – SEM, n = 3. #p < 0.01 vs.
si-NTC or si12-LO, $p < 0.01 vs. siNTC+TGF-b). 12/15-LO,
12/15-lipoxygenase; TGF-b, transforming growth factor-b.
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first time that oxidized lipids such as 12(S)-HETE from 12/
15-LO can directly promote epigenetic histone modification
changes involved in profibrotic gene expression, at least in
part via SET7, and that 12/15-LO also mediates similar ef-
fects elicited by TGF-b in MCs. Furthermore, 12/15-LO
deficiency in mice ameliorates DN in vivo and inhibits
diabetes-induced expression of TGF-b and profibrotic genes,
as well as SET7. These results suggest an important role for
12/15-LO and its key lipid metabolites in regulating epige-
netic mechanisms involved in the pathogenesis of DN.
We observed that the oxidized lipid 12(S)-HETE increased
the enrichment of histone lysine modifications associated with
active gene expression such as H3K9Ac and H3K4me at pro-
fibrotic gene promoters in MCs. This suggests that 12(S)-HETE
can promote open chromatin formation accessible to tran-
scription factors involved in the expression of these genes. We
previously reported that 12(S)-HETE could regulate Smad
activity (22). The ChIP primers we used in the study were near
Smad binding sites, suggesting 12(S)-HETE might promote
Smad-induced gene expression by acetylation-mediated chro-
matin relaxation.
Several lines of evidence support a key role for the 12/15-
LO pathway of arachidonate metabolism in the pathogenesis
of DN. 12/15-LO is highly expressed in the kidney and is
induced under diabetic conditions, both in vitro in MCs and
in vivo in type 1 and type 2 diabetes models (15, 40, 57, 58).
12/15-LO and its lipid products contribute to cellular hy-
pertrophy and regulate the expression of profibrotic, proin-
flammatory, and growth factor receptor genes (11, 40, 58, 59,
61). Targeting 12/15-LO expression using cholesterol-tagged
siRNAs alleviated ECM expansion, glomerular hypertrophy,
and albuminuria in kidneys of type 1 diabetic mice (61). An-
other study showed that a chemical inhibitor of 12/15-LO
ameliorated proteinuria and renal hypertrophy in type 2 diabetic
rats (58). In the current study, we demonstrate for the first time
that genetic knockdown of 12/15-LO in mice (LOKO mice)
significantly attenuated proteinuria, glomerular hypertrophy,
and fibrosis, providing further clear support for the in vivo in-
volvement of 12/15-LO in DN. Reactive oxygen species (ROS)
and lipid peroxidation are important in the pathogenesis of DN.
Multiple factors related to DN are involved in the production of
ROS, including hyperglycemia, advanced glycation end prod-
ucts, growth factors, and cytokines (4). 12/15-LO can also
promote ROS production, lipid peroxidation (7), and superox-
ide anions (30). Several studies demonstrated that increased
expression and activation of 12/15-LO lead to increased pro-
duction of oxidized lipid products in kidneys of animals with
DN (6, 15, 32, 40). Furthermore, 12/15-LO deficiency reduces
oxidative stress in renal and vascular cells (21, 41), and in-
creased expression of 12/15-LO and levels of 12(S)-HETE are
associated with enhanced oxidative stress in prediabetic kidneys
(6). Therefore, 12/15-LO is one of the key factors involved in
ROS production and lipid peroxidation involved in the patho-
genesis of DN.
Epigenetic changes in chromatin such as PTMs of histone
tails, including lysine methylation and acetylation, have been
demonstrated in regulation of genes associated with DN (23,
42, 43, 52, 62). We recently demonstrated that HG and TGF-
b treatment of MCs led to increased levels of H3K9Ac and
H3K4me (gene activation) and decreased levels of repressive
A
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FIG. 5. TGF-b-induced profibrotic gene expression and permissive histone modifications at these promoters were
attenuated in MCs from 12/15-LOKO mice. (A–D) TGF-b-induced profibrotic gene expression was attenuated in MMCs
from LOKO mice. MCs cultured from WT and LOKO mice were SD for 24 h, and then treated with TGF-b (10 ng/ml) from
0.5 to 4 h. Expression of Serpine1 (A), Ctgf (B), Setd7 (C), and Ppia (D) was analyzed by RT-qPCR using b-actin as internal
control. The results are expressed as fold over SD (mean – SEM, n = 3. #p < 0.01 vs. SD). (E–J) TGF-b-induced enrichment
of H3K9Ac (E–G) and H3K4me1 (H–J) at profibrotic gene promoters was attenuated in MCs from LOKO mice. Quiescent
MCs from WT and LOKO mice were treated with TGF-b (10 ng/ml) for 2 h, ChIP assays were performed as described in
Figure 2 with indicated antibodies, and ChIP-enriched DNA samples were amplified with primers specific to the profibrotic
gene promoters. Results normalized to input DNA are expressed as fold enrichment over untreated WT MC (mean – SEM,
n = 3; *p < 0.05, #p < 0.01, $p < 0.01). LOKO, LO knockout; MMC, mouse mesangial cell; WT, wild-type.
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H3K9me at promoters of profibrotic genes, as well increased
expression of SET7 and its recruitment at profibrotic gene
promoters (52, 62). Furthermore, a TGF-b antibody abol-
ished HG-induced ECM gene expression and corresponding
changes in histone modifications at their promoters (52).
These observations suggest that targeting of TGF-b actions
can reverse key epigenetic changes associated with diabetic
complications. However, because targeting TGF-b itself can
have adverse effects due to its important roles in immune
cells, we explored key modulators and effectors of TGF-b-
mediated epigenetic effects. We therefore examined 12/15-
LO in this study because our previous studies demonstrated
that a cross talk between these two key factors amplifies
signal transduction cascades involved in hypertrophic and
profibrotic gene expression associated with diabetic renal
dysfunction (22). Most notably, in the current study, we
found that 12/15-LO deficiency attenuated TGF-b-induced
histone modifications (H3K9Ac and H3K4me1) at profibrotic
gene promoters and SET7 expression. These new results
suggest that 12/15-LO can mediate key epigenetic effects of
TGF-b, leading to expression of profibrotic genes in MCs.
Our data showed increases in H3K4me1 at profibrotic
promoters, suggesting a critical role of this modification in
MCs. Evidence shows that SET7 mediates H3K4me1 associ-
ated with gene activation under diabetic conditions in mono-
cytes, endothelial cells, and MCs and also cooperates with NF-
jB (27, 37, 52). SET7 plays a role in gene transactivation by
competing with HDACs to enhance H3K9Ac and prevent
H3K9me (34, 56). In addition, SET7 can downregulate the
repressive H3K9me3 methyltransferase activity of SUV39H1
(55). Furthermore, hyperglycemia could induce NF-jB (p65)
gene expression in endothelial cells via increased H3K4me1
and decreased repressive modifications, H3K9me2 and
H3K9me3 (3). Further studies showed that HG increased
SET7 enrichment at the p65 promoter and its knockdown re-
duced H3K4me1 and attenuated increases in p65 expression.
We previously showed that SET7 regulates TGF-b-induced
profibrotic gene expression in MCs (52) and inflammatory
gene expression in diabetic macrophages (27). Our current
data also showed that 12(S)-HETE-induced increases in per-
missive histone PTMs and recruitment of SET7 correspond to
increased expression of fibrotic genes, but not all the changes
Table 1. Physiological Parameters in Experimental Groups
Parameter WT+NS WT+STZ LOKO+NS LOKO+STZ
Fasting glucose 1 week (mg/dl) 144 – 15.0 331 – 46.4a 156 – 2.1 263 – 58.2
Fasting glucose 12 weeks (mg/dl) 197 – 13.5 558 – 14.3b 156 – 6.8 439 – 72.3c
Fasting glucose 16 weeks (mg/dl) 140 – 13.9 539 – 28.5b 155 – 8.57 617 – 58.4d
Serum creatinine 16 weeks (mg/dl) 0.20 – 0.01 0.14 – 0.03 0.20 – 0.01 0.17 – 0.01
Body weight 1 week (g) 24.77 – 0.82 22.57 – 0.58 25.27 – 2.07 25.47 – 0.29
Body weight 12 weeks (g) 30.00 – 1.53 25.67 – 1.45 28.33 – 2.96 28.00 – 1.15
Body weight 16 weeks (g) 31.00 – 1.53 26.00 – 1.53 30.00 – 3.21 29.33 – 1.33
Kidney weight 16 weeks (g) 0.412 – 0.013 0.471 – 0.061 0.436 – 0.082 0.515 – 0.056
K/B weight (%) 1.330 – 0.059 1.810 – 0.076e 1.456 – 0.114 1.742 – 0.054f,g
Values are mean – SE; n = 3 per group. C57BL/6 and LOKO mice were injected with STZ for 5 days. Nondiabetic groups of C57BL/6
and LOKO mice were injected with citrate buffer alone. Parameters were first measured at 1 week after establishment of hyperglycemia.
ap < 0.05 versus WT+NS.
bp < 0.001 versus WT+NS.
cp < 0.01 versus LOKO+NS.
dp < 0.001 versus LOKO+NS.
ep < 0.01 versus WT+NS.
fp < 0.05 versus LOKO+NS.
gp < 0.05 versus WT+STZ.
LOKO, lipoxygenase knockout; NS, no streptozotocin; SE, standard error; STZ, streptozotocin; WT, wild-type.
Table 2. Urinary Parameters in Experimental Groups
Parameter WT+NS WT+STZ LOKO+NS LOKO+STZ
Urinary volume 1 week (ml) 2.23 – 0.38 19.83 – 3.11a 4.60 – 0.35 12.50 – 7.17
Proteinuria 1 week (mg) 23.68 – 3.10 31.57 – 2.96 22.76 – 4.74 30.86 – 4.03
Urinary CR 1 week (mg/dl) 14.71 – 0.98 7.40 – 0.86b 11.07 – 0.60 10.03 – 2.15
Urinary volume 12 weeks (ml) 1.83 – 0.88 27.67 – 1.20b 3.00 – 0.81 28.67 – 8.37c
Proteinuria 12 weeks (mg) 22.45 – 5.50 75.92 – 9.61a 24.79 – 6.42 60.95 – 10.04c
Urinary CR 12 weeks (mg/dl) 13.95 – 1.06 5.90 – 0.33b 12.49 – 0.66 7.12 – 1.50
Urinary volume 16 weeks (ml) 1.40 – 0.64 35.33 – 0.88b 3.33 – 0.38 22.67 – 5.90c
Proteinuria 16 weeks (mg) 27.88 – 5.24 80.46 – 13.54a 21.48 – 1.99 66.14 – 11.14c
Urinary CR 16 weeks (mg/dl) 17.77 – 1.60 7.40 – 0.86b 10.59 – 1.08 10.03 – 2.15
Values are mean – SE; n = 3 per group. C57BL/6 and LOKO mice were injected with STZ for 5 days. Nondiabetic groups of C57BL/6
and LOKO mice were injected with citrate buffer alone. Parameters were first measured at 1 week after establishment of hyperglycemia.
ap < 0.01 versus WT+NS.
bp < 0.001 versus WT+NS.
cp < 0.05 versus LOKO+NS.
CR, creatinine.
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observed were sustained during the entire time course. These
results demonstrate promoter and modification-specific dif-
ferences in the formation of accessible chromatin needed for
active gene expression. Furthermore, dynamic changes in
chromatin remodeling arise from the cumulative effects and
collaboration between several histone modifications. Thus, all
histone modifications need not be altered simultaneously to
sustain the chromatin relaxation involved in long-term gene
expression. In addition, unlike the in vitro treatment with a
single stimulus such as 12(S)-HETE, several pathological
factors can act together in vivo, which can further amplify and
sustain the alterations in chromatin structure involved in
disease-associated gene expression. Altogether, these studies
implicate SET7 as one of the key regulators of gene expression
under diabetic conditions in diverse cell types involved in di-
abetic complications.
Interestingly, in the current study, we found that 12(S)-
HETE directly increased SET7 protein levels and promoted its
nuclear translocation, as well as occupancy, at the profibrotic
gene promoters. Furthermore, TGF-b-induced SET7 expres-
sion was inhibited by 12-LO siRNA, and SET7 expression was
attenuated in LOKO-MC, demonstrating a role for 12/15-LO
and its oxidized lipid products in TGF-b-mediated SET7 ex-
pression. Evidence shows that nuclear translocation of SET7
can also be induced by HG in endothelial cells (37). Because,
HG and diabetes can also increase 12/15-LO and 12(S)-HETE
FIG. 6. Proteinuria, glomerular hypertrophy, and ECM deposition were less pronounced in diabetic LOKO mice.
(A) Urine albumin/creatinine ratio (lg/mg) in urine samples from diabetic (STZ) and control (NS) WT and LOKO mice at
12 and 16 weeks postdiabetes. Biochemical assays were performed as described in the Materials and Methods section.
*p < 0.05 versus LOKO+NS; #p < 0.01 versus WT+NS, Data represent mean – SEM (n = 3). (B) Representative images of
PAS staining and (C) quantification of glomerular area and mesangial expansion in kidneys from diabetic (STZ) and control
(NS) WT and LOKO mice. Data represent mean – SEM (n = 3). #p < 0.01 versus WT+NS or LOKO+NS, $p < 0.01 versus
WT-STZ. (D) Representative images of indicated staining in kidney sections from WT and LOKO mice at 16 weeks
postdiabetes. Images of H&E staining (1–4), PASM staining (5–8), Masson’s trichrome staining (9–12), and TGF-b
immunostaining in kidney sections from WT+NS (1, 5, 9, 13), WT+STZ (2, 6, 10, 14), LOKO+NS (3, 7, 11, 15), and
LOKO+STZ mice (4, 8, 12, 16). (E, F) Quantification of Masson’s trichrome-positive area and (E) and TGF-b-positive area
(F) in the glomeruli using Image-Pro plus software and expressed as fold over WT+NS (n = 6). Values are mean – SEM.
#p < 0.01 versus WT+NS, $p < 0.01 versus WT-STZ. ECM, extracellular matrix; H&E, hematoxylin and eosin; NS, no
streptozotocin; PAS, periodic acid-Schiff; PASM, periodic acid-silver methenamine; STZ, streptozotocin.
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levels in MCs, SET7 may be a key target by which increased
12/15-LO and its products regulate pathologic genes involved
in DN. Furthermore, similar mechanisms may be operative in
endothelial cells and vascular smooth muscle cells, in which
the 12/15-LO pathway is activated under diabetic conditions
(26, 31, 45, 47), thereby contributing to multiple vascular
complications. Thus, evidence shows that LO products and 12/
15-LO can mediate low-density lipoprotein oxidation and are
augmented in atherosclerosis, diabetes, and obesity and can
mediate the development of diabetes and its key complica-
tions, including DN (8, 32, 33, 38).
The in vivo involvement of SET7 in diabetic complications
is not fully clear. We speculated that there could be a cross
talk between the TGF-b and 12/15-LO pathways in regulat-
ing SET7 expression in diabetic kidneys. In support of this,
we observed that SET7 levels were enhanced in renal cortices
and glomeruli from STZ-injected diabetic mice relative to
nondiabetic mice, along with increases in TGF-b, 12/15-LO,
and profibrotic genes. Importantly, 12/15-LO gene silencing
by cholesterol-tagged siRNA injection or genetic knockdown
(LOKO mice) significantly abrogated these diabetes-induced
effects. A recent study showed increased expression of SET7
in kidneys from type 2 diabetic db/db mice, where it was
implicated in monocyte chemoattractant protein-1 (MCP-1)
expression (5), further highlighting the importance of SET7
in DN pathogenesis.
In summary, our study with in vitro and in vivo models
demonstrates that the 12/15-LO pathway is involved in dia-
betes and TGF-b-associated signaling, histone modifications,
and SET7 regulation associated with the sustained expression
of multiple profibrotic genes involved in the progression of
DN (Fig. 8). Apart from its role in HG and TGF-b effects, 12/
15-LO also regulates AT1R expression and mediates Ang II
effects (32, 40, 45, 59). 12/15-LO may therefore also mod-
ulate histone modifications mediated by Ang II under dia-
betic conditions. Thus, 12/15-LO could be a key common
mediator of epigenetic mechanisms induced by multiple
factors involved in DN pathogenesis. Therefore, inhibitors of
the 12/15-LO pathway might offer novel therapeutic oppor-
tunities for DN by targeting these epigenetic changes. This
has translational significance because epigenetic mechanisms
may be key factors responsible for the relative inefficacy of
traditional drugs used for DN, such as Ang II-converting
enzyme inhibitors and AT1R blockers (48), and also for
metabolic memory, the phenomenon in which periods of poor
glycemic control can lead to continued sustained progression
of diabetic complications such as DN, despite subsequent
good glycemic control (20, 44).
FIG. 7. Increases in profibrotic genes and SET7 were
attenuated in diabetic LOKO mice and diabetic mice
treated with si12-LO. (A) Expression of profibrotic genes in
glomeruli from diabetic (STZ) and control (NS) WT and
LOKO mice. Kidneys from two mice were pooled to collect
glomeruli from each group of mice, total RNA was extracted
and profibrotic gene expression was determined by RT-
qPCR. Profibrotic gene expression was normalized using b-
actin and expressed as fold over nondiabetic control. Data
represent mean – SEM (n = 3). #p < 0.01 versus WT or LOKO,
$p < 0.01 versus WT+STZ. (B) Total RNA isolated from renal
cortex or pooled glomeruli was used to analyze expression of
Setd7 mRNA by RT-qPCR from diabetic (STZ) and control
(NS) WT and LOKO mice. Values are mean – SEM (n = 3).
*p < 0.05, $p < 0.01. (C, D) Total protein lysates from pooled
glomeruli (C) and renal cortex (D) were immunoblotted with
indicated antibodies. Results show that the increases in SET7
and profibrotic Serpine1 expression seen in diabetic WT mice
are absent in diabetic LOKO mice compared with respective
controls. (E) Expression of Setd7 mRNA in renal cortex from
control nondiabetic mice (NS), control diabetic mice (STZ),
diabetic mice injected with 12/15-LO siRNA (si12-
LO+STZ), or control siRNA (mismatched oligos [MM],
siMM+STZ). Total RNA from indicated mice was analyzed
by RT-qPCR and Setd7 expression was expressed as fold
over nondiabetic control (NS). Values are mean – SEM
(n = 4). *p < 0.05, #p < 0.01 versus NS. (F) Protein lysates
from indicated mice were immunoblotted with SET7, Ser-
pine1, and b-actin antibodies.
‰
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Materials and Methods
Materials
12(S)-Hydroxyeicosa-5Z, 8Z, 10E, 14Z-tetraenoic acid
[12(S)-HETE], and its stereoisomer, 12(R)-HETE, were from
Biomol (Plymouth Meeting, PA); pan-specific TGF-b1 an-
tibody (MAB1835) and recombinant human TGF-b1 (240-
B) were obtained from R&D Systems (Minneapolis, MN);
lamin B1 (9087) antibody and horseradish peroxidase-
conjugated secondary antibodies were from Cell Signaling
(Beverly, MA); anti-SET7 (ab14820), anti-H3K9 acetylation
(ab10812), anti-H3 monomethyl K4 (ab8895), anti-H3 di-
methylK4 (ab32356), and anti-H3 trimethyl K4 (ab8580)
were from Abcam (Cambridge, MA); purified mouse anti-
PAI-1 (612024) was from BD Biosciences (San Jose, CA);
normal rabbit IgG (PP64B) and normal mouse IgG (12-371)
were from Upstate Biotechnology, and b-actin antibody was
from Sigma (St. Louis, MO). SET7 ON-TARGET plus
Smartpool siRNA ( J-059399[09–12]), leukocyte-type 12-LO
ON-TARGET plus Smartpool siRNA ( J-083898[09-12]),
and silencer nontargeting control siRNA #1 (D-001810-01-
05) were from Thermo Scientific (Waltham, MA); RNA-
STAT60 reagent was from Tel-Test (Friendswood, TX) and
RNeasy columns were from Qiagen (Valencia, CA). Reverse
transcriptase kits and SYBR Green PCR Master Mix kits
were from Applied Biosystems (Foster City, CA). Sequences
of the qPCR primers used in this study are listed in Table 3.
Cell culture
Primary cultures of RMCs from Sprague-Dawley rats, and
mouse mesangial cells (MMCs) from genetic control mice
(C57BL/6, WT) and leukocyte-type 12/15-LOKO mice
(Strain B6. 129S2-Alox15tm1Fun; Jackson Laboratories, Bar
Harbor, ME) were prepared as described previously (21, 52).
Briefly, kidney cortices from mice (8–10 weeks old) or rats
(250–300 g) were minced and the glomeruli were isolated
by differential sieving. Then, glomeruli were digested with
collagenase (Sigma Chemical Co., Inc., St. Louis, MO, USA)
for 15 minutes and cultured in T-25 culture flasks (Nunc,
Rochester, NY, USA) in RPMI 1640 medium supplemented
with 15% fetal calf serum (FCS) (Omega Scientific, Co.,
Tarzana, CA, USA) and 20 lg/mL insulin (Sigma Chemical
Co.) at 37C under 5% CO2 for about a week to 10 days until
outgrowths of spindle-like mesangial cells were observed.
Then mesangial cells were cultured for a further 48 hours in
the presence of 50 mmol/L D-valine containing medium to
exclude fibroblasts. Purity of MC was tested by staining cells
plated on glass chamber slides with monoclonal Thy1.1 an-
tibody. MCs were maintained in RPMI 1640 supplemented
with L-glutamine (2.5 mM), HEPES (7 mM), Penicillin/
streptomycin and 10% fetal calf serum. Cells between 5 to 12
passages were used in all the studies.
Transient transfection
MCs were placed in 60-mm dishes upto 75% confluency,
then cotransfected with 0.3 lg of 12-LO ON-TARGETplus
Smartpool siRNA (si12-LO) or Silencer Negative Control #1
siRNA (siNTC) using Nucleofection reagent as described
earlier (17). After the transfected cells recovered, they were
placed in serum-free RPMI 1640 medium containing 0.2%
bovine serum albumin for 24 h, treated with or without TGF-
b (10 ng/ml), and processed for RNA extraction at the indi-
cated time periods. In SET7 gene silencing experiments,
RMCs were transfected using Smartpool siSET7 (siSET7) or
siNTC (20 nM) using RNAiMAX (Lifetechnologies, Carls-
bad, CA). After 2 days, cells were retransfected with siSET7
or siNTC, and 48 h after the second transfection, cells were
treated with vehicle or 12(S)-HETE. Total RNA was ex-
tracted and gene expression was determined by RT-qPCR.
RNA isolation and RT-qPCR
Total RNA was isolated from MCs, renal cortices, and
glomeruli using RNA-STAT60 reagent and RNeasy columns
according to the manufacturer’s instructions. Total RNA
(0.5–1 lg) was used for cDNA synthesis using Gene Amp
RNA PCR kits (Applied Biosystems) and qPCRs were per-
formed in triplicate in a final volume of 20 ll with an ABI
7500 real-time PCR thermal cycler (Applied Biosystems)
using specific gene primers as described previously (52,61).
Dissociation curves were run to detect nonspecific amplifi-
cation and to confirm amplification of a single product in each
reaction. Data was analyzed by 2-DDCt method using Actb,
FIG. 8. Model for the role of the 12/15-LO pathway in
HG or TGF-b-induced histone modifications and gene
expression. The 12/15-LO pathway and its oxidized lipid
metabolites such as 12(S)-HETE induce dynamic changes in
permissive histone modifications and promote SET7 nuclear
translocation, as well as its occupancy, at target gene pro-
moters such as Serpine1 and Ctgf. These events play
important roles in mediating HG or TGF-b-induced epige-
netic changes involved in profibrotic gene expression.
Deficiency of 12/15-LO attenuates these responses. Thus,
cross talk between 12/15-LO and TGF-b pathways can lead
to sustained expression of profibrotic genes involved in the
progression of DN. DN, diabetic nephropathy; HG, high
glucose. To see this illustration in color, the reader is referred
to the web version of this article at www.liebertpub.com/ars
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Ppia or Rplp0 genes as internal controls (52,61). Results were
expressed as fold over control.
Western blots
Protein lysates from MCs, glomeruli, and renal cortex
tissues were prepared by using 1.5· sodium dodecyl sulfate
(SDS) sample buffer and immunoblotting was performed as
described previously (61, 62). Nuclear extracts were prepared
using the NE-PER kit (Cat#78833; Thermo Scientific) ac-
cording to the manufacturer’s protocols.
ChIP assays
Quiescent RMCs were treated with 12(S)-HETE for the
indicated time points, and then fixed with 1% formaldehyde
for 10 min at room temperature, followed by neutralization
with 125 mM glycine for 5 min. Fixed cells were washed
three times with cold phosphate-buffered saline supplemen-
ted with protease inhibitors and lysed using 1% SDS lysis
buffer supplemented with protease inhibitors. Cell lysates
were sonicated until DNA was fragmented up to 200–
1000 bp. Chromatin immunoprecipitation (ChIP) assays with
the relevant antibodies indicated above under the Materials
section were performed using commercially available kits
(EMD Millipore, New York, NY) as described previously
(52). Cell lysates were diluted with ChIP dilution buffer to
reduce SDS concentration to < 0.1%, precleared by incubat-
ing with Protein A/G agarose beads for an hour. Then, lysates
were centrifuged and supernatants were incubated with in-
dicated antibodies (1–5 lg) overnight at 4C. Next day,
protein A/G-coupled agarose beads were added and 2 h later
beads were collected by centrifugation. Beads were washed
sequentially with low-salt buffer, high-salt buffer, LiCl buf-
fer, and TE buffer at 4C. Washed beads were incubated with
elution buffer (1% SDS in 0.1 M NaHCO3) at room tem-
perature for 15 min to elute immune complexes. DNA-
protein cross links were removed by incubation at 65C for
4 h. Then, ChIP-DNA was extracted by digestion with pro-
teinase K (50 lg/ml) for 30 min, followed by extraction with
phenol–chloroform and precipitation of DNA from the
aqueous layer using two volumes of ethanol at -20C over-
night. An aliquot of the cell lysate was used to isolate total
input DNA. Rabbit or mouse IgG was used as antibody
controls. Using qPCR, we confirmed the enrichment (15- to
12,000-fold enrichment) of histone modifications at gene
promoters relative to IgG samples demonstrating specificity
of ChIP assays. Furthermore, Western blots also showed that
these antibodies detected specific bands corresponding to
histone proteins in RMC lysates. Input DNA samples as well
as antibody-enriched ChIP DNA samples were analyzed by
qPCR using primers corresponding to sequences within the
promoter regions near Smad binding sites for profibrotic
genes (Table 3). Data were analyzed using the 2-DDCt method
and normalized as described (52). Results are expressed as
fold over respective control samples.
Immunofluorescence
Confluent RMCs were placed on glass slides, SD, and
treated with 12(S)-HETE (10-7 M), followed by IF as de-
scribed before (27). Cellular localization of stained protein
was observed under a fluorescent microscope (Olympus,
Tokyo, Japan). To detect the nuclei, cells were stained with
0.2% Hoechst 33342 (Molecular Probe, Eugene, OR).
Mouse models of DN
All animal studies were conducted using protocols ap-
proved by the Institutional Research Animal Care and Use
Committee (IACUC). The animals were housed in a
temperature-controlled room and given free access to water
and standard laboratory chow. To induce type 1 diabetes,
about 8-week-old WT and LOKO mice (n = 6) were injected
with 50 mg/kg of STZ intraperitoneally for 5 consecutive
days as described earlier (39). Nondiabetic control mice were
Table 3. Primer Sequences Used in This Study
Primer Forward primer Reverse primer
cDNA primers
Serpine1 (R) cggaCTTCTTCAAGCTCTTCCG TGAAATAGAGGGCGTTCACCAG
Col1a1 (R) TGGTGCTCCTGGTATTGCTG cggaCGTTTTCCTTCTTCTCCG
Ctgf (R/m) cagctCCGAGAAGGGTCAAGCTG AACAGGCGCTCCACTCTGTG
Setd7 (R) ACAGAAGAAGGGAAGCCACA CGGACTCATAAGGGTCTGGA
Actb (R/m) CTGCCCTGGCTCCTAGCAC cggacGCAGCTCAGTAACAGTCCG
Serpine1 (m) GACGCCTTCATTTGGACGAA CGGACCTTTTCCCTTCAAGAGTCCG
Col1a1 (m) CGGATAGCAGATTGAGAACATCCG CGGCTGAGTAGGGAACACACA
Col4a1 (m) CACGAGCTTCCCTGGTAGTCGTG GGACAACCTTTCCTGCCTCA
Tgfb1 (m) AGGAAGGACCTGGGTTGGAAG CGTCTCGACCCACGTAGTAGACG
Rplp0 (m) GCCCTGCACTCTCGCTTTCT CAACTGGGCACCGAGGCAACAGTTG
Setd7 (m) GGGAAGTTCATTGACGGAGA AGGGTCTGGAAGGAGAGCAT
ChIP primers
Serpine1 pro (R) cggcTATACCAGATGTGGGCcG GACGACCGACCAGCCAAAG
Col1a1 pro (R) GGCTGGAGAAAGGTGGGTCT CCCAGGTATGCAGGGTAGGA
Ctgf pro (R) ATCAGGAAGGGTGCGAAGAG TCCACATTCCTCCGTCTGAA
Ppia pro (R) TATCTGCACTGCCAAGACTGAGTG CTTCTTGCTGGTCTTGCCATTCC
Serpine1 pro (m) cggcCTTTATACCAGATGTGAGCcG TCCAAACACCAGGCTTTGTAGG
Col1a1 pro (m) TGGACTCCTTTCCCTTCCTT CTGGGCCCCTTTTATACCAT
Ctgf pro (m) AGCCAGAACTGGCAAAGAGA ACACTTTAGCTCGCCAGGAA
ChIP, chromatin immunoprecipitation; m, mouse; R, rat.
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injected with citrate buffer (NS). All mice were euthanized at
16 weeks after development of diabetes (blood glucose levels
>350 mg/dl in STZ versus 140 mg/dl in control mice). Blood
samples were collected before euthanization. Individual mice
were placed in metabolic cages to collect 24-h urine samples
during the first, 12, and 16 weeks postdiabetes. Renal cortical
tissues were saved for Western blots and qPCRs. Glomeruli
were isolated from cortical tissues by sequential sieving as
described before (62) and pooled from two mice in each
group. Body weight and blood glucose were checked
monthly, and kidneys were weighed after the animals were
euthanized. Treatment of diabetic mice with the cholesterol-
tagged siRNAs targeting 12/15-LO or control siRNAs was
described earlier (61). Briefly, diabetes was induced by in-
jecting STZ (50 mg/kg) for 5 days in 8-week-old DBA/2J
mice. Diabetic mice (glucose >300 mg/dl) were subcutane-
ously injected with normal saline or cholesterol-tagged 12-
LO siRNAs or mismatched siRNAs (MM oligos) for 7 weeks
(400 lg each, twice/week). As controls, nondiabetic mice
were injected with normal saline (61). After 7 weeks, mice
were euthanized and kidneys were collected for further
processing.
Urinary protein and albumin assay
Urine samples (24 h) were diluted 5· with Milli Q distilled
water and the amount of protein (in milligrams) was deter-
mined using detergent-compatible protein assay kits (Bio-Rad,
Inc., Hercules, CA) as described previously (39). Urinary al-
bumin concentration was measured with an indirect competi-
tive ELISA kit (Exocell, Philadelphia, PA) according to the
manufacturer’s instructions.
Histology and morphology analyses
Renal cortices were fixed immediately after harvesting in
10% neutral buffered formalin solution and submitted to the
Anatomic Pathology Core at the City of Hope Medical
Center to obtain paraffin-embedded sections. To evaluate
diabetes-associated renal pathological changes, sections
were processed for hematoxylin and eosin, periodic acid-
silver methenamine, and Masson’s trichrome staining.
Images were captured using an Olympus DP72 Microscope
Digital Camera and processed with DP2-BSW software.
The areas of glomeruli and mesangial expansion were
quantified using Image-Pro (version 5.1; Media Cyber-
netics, Silver Spring, MD).
Immunohistochemical staining
IHC staining was performed as described (19, 61) using
TGF-b1 antibody (1:100 dilution) for 0.5 h at room temper-
ature. Twenty glomeruli in each section were examined using
light microscopy at a magnification of 400·, and stained positive
area per glomerulus was quantified using Image-Pro software.
Statistical analyses
Data are expressed as mean – standard error of the mean of
multiple experiments. Paired Student’s t-tests were used to
compare two groups or ANOVA with Dunnet’s post-test for
multiple groups using PRISM software (Graph Pad, San
Diego, CA). Statistical significance was detected at the 0.05
level.
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Ang II¼ angiotensin II





H&E¼ hematoxylin and eosin
H3K4me1¼ histone H3 lysine-4 monomethylation
H3K4me3¼ histone H3 lysine-4 trimethylation









NF-jB¼ nuclear factor of kappa light polypeptide
gene enhancer in B-cells
NS¼ no streptozotocin
PAS¼ periodic acid-Schiff
PASM¼ periodic acid-silver methenamine
PTMs¼ post-translational modifications
RMC¼ rat mesangial cell
ROS¼ reactive oxygen species
RT-qPCR¼ real-time quantitative polymerase chain
reaction
SD¼ serum depleted
SDS¼ sodium dodecyl sulfate
SE¼ standard error
SEM¼ standard error of the mean
SET7¼ SET domain containing (lysine
methyltransferase) 7
si12-LO¼ siRNA targeting 12/15-LO
siMM¼ control nontargeting siRNA
siNTC¼ nontargeting siRNA
STZ¼ streptozotocin
TGF-b1¼ transforming growth factor-b1
WT¼wild-type
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